Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

RT With Or Without Temozolomide (E3F05)

NCT00978458

ECOG-ACRIN · Phase 3 · Active, not recruiting · Enrollment 540

NCT00978458

Catalyst Primary completion. 12.31.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy

No efficacy figure is in this file for this study.